Autologous vs Allogeneic Cell Therapy

Published: March 2024


Cell therapy involves the use of living cells to replace or repair damaged tissues, thereby preventing or treating a variety of indications. Further, the different types of cell therapies include dendritic cells, hematopoietic stem cells, lymphocytes, mesenchymal stem cells, pancreatic islet cells and skeletal muscle stem cells. These cell therapies have different isolation methods, mechanism of action, immunophenotypic profiles and regulatory levels. In addition, the cell therapies can be distinguished on the basis of cell source into autologous cell therapy and allogeneic cell therapy. In case of autologous cell therapy, the source of cells are the patients themselves, whereas in case of allogeneic cell therapy the cells are extracted from a healthy donor.

Roots Analysis has conducted an exhaustive study on the Allogeneic Cell Therapy Market featuring the current market landscape, competitive landscape and future opportunity, over the forecast period 2023-2035.

Discover the Details on Types of Cell Therapies and The Driving Factors for the Move Towards Allogeneic Cell Therapies

This article highlights the different types of cell therapies, differentiating factors and the factors driving the demand for allogeneic cell therapies.

Distinguishing Factors by Source of Cells

The following table presents the difference between both the autologous and allogeneic cell therapies.

Parameter Autologus Cell Therapies Allogenic Cell Therapies
Source of Cell The cells are derived from the same individual receiving the treatment The cells are derived from an individual other than the one receiving the treatment 
Type of Therapy Customized products (Suitable for specific individual) Off-the-shelf products (Suitable for different individuals)
Scale of Manufacturing  Manufactured as a single lot Manufactured in large batches
Availability Limited availability Wide availability (of cryopreserved stocks)
Production Cost Expensive due to personalized nature Cost effective due to mass production
Risk of Rejection Lower risk of rejection by the recipient’s immune system (Avoids graft-versus-host disease)  High risk of rejection by the recipient’s immune system


Progress With Allogeneic Cell Therapy

More than 470 allogeneic cell therapies are currently being evaluated across various stages of development for different patient segments; further, eleven allogeneic cell therapies have been approved, till date. Around 75% of the allogeneic cell therapies are in clinical phase of development; of these, majority are in phase I, followed by those in phase I/II and phase II. Notably, close to 130 T-cell allogeneic cell therapies (such as CAR T cell therapy, gamma delta T-cell, virus-specific T-cell, regulatory T-cell (Treg therapy), TCR therapy and TIL therapy),  are currently being developed for the treatment of different oncological disorders.

The Need for Allogeneic Cell Therapy

The lessons learnt from the development and manufacture of autologous cell therapies have helped in laying a robust foundation for the high potential and exciting field of allogeneic cell therapies. The allogeneic approach mitigates concerns related to variability in cell quality as well as quantity (that may arise with autologous approach). Moreover, these therapies expediate the development timelines and streamline the regulatory process, facilitating quicker access to novel therapeutics for a wide range of individuals.

Key Allogeneic Cell Therapy Companies

Below, we have listed (in decreasing order of the number of allogeneic cell therapies developed), the top 5 allogenic cell therapy developers:

Company YoE Headquarters
  (State, Country)   
Highest Stage of
         Development          
Fate Therapeutics 2007 California, US Phase I
Allogene Therapeutics  2017 California, US IND Enabling
GC Cell 2011 Gyeonggi-do, South Korea Phase I / II
Artiva Biotherapeutics 2019 California, US Phase I / II
CHA Biotech 2002 Seoul, South Korea Phase II


Future Perspective

The trajectory of allogeneic cell therapies appears promising, owing to the ongoing advancements poised to revolutionize the landscape of regenerative medicine. The increase in allogeneic cell therapies demonstrates a shift towards scalable, cost-effective and widely applicable solutions. As research and development efforts continue, we anticipate refined manufacturing approaches, increased understanding of immunogenicity and enhances precision in regenerative medicine domain.

Wish to Gain an In-Depth Analysis on the Allogeneic Cell Therapy Market?

We have conducted in-depth research on the market landscape of allogeneic cell therapy, understanding the stage of development, competitive landscape, market opportunity, key trends and future outlook. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com

About Author

Simran Kaur

Simran, a Senior Business Analysis, has been an integral part of the Roots Analysis team since 2020. Holding a Master’s and Bachelor’s in pharmacy from a prestigious institution, she embarked on her professional journey with a strong academic foundation and an interest in life sciences domain. Her keenness to learn more about the emerging trends, regulatory dynamics and technological advancements enables her to provide comprehensive analyses. Till date, she has diligently contributed to over 15 comprehensive research reports on trending topics, ranging from anti-aging therapeutics, allogeneic cell therapies, lipid nanoparticles, pre-sterilized pharmaceutical packaging to next generation sequencing kits.

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry